Findings

What do systematic reviews say?

20 questions · 20 findings · 2 reviews · Dementia and Cognitive Improvement

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 10%GRADE not reported 0 · 0%Very low 2 · 10%Low 4 · 20%Moderate 10 · 50%High 2 · 10%

Summary of findings ‐ Typical antipsychotics vs placebo

Specific behaviour ‐ agitation

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Summary of findings ‐ Typical antipsychotics vs placebo

Response for agitation ‐ as defined by authors of RCTs ‐ 1303 persons in 4 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Summary of findings ‐ Typical antipsychotics vs placebo

Psychosis ‐ presented in units of NPI‐NH P (higher is worse)d ‐ 3364 persons in 12 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Summary of findings ‐ Typical antipsychotics vs placebo

Response for psychosis ‐ as defined by authors of RCTs ‐ 1958 persons in 7 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Summary of findings ‐ Typical antipsychotics vs placebo

Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
High

Summary of findings ‐ Typical antipsychotics vs placebo

Somnolence

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Summary of findings ‐ Typical antipsychotics vs placebo

Death ‐ 5032 persons in 17 RCTs of 3 to 12 weeks ___________________________________________

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Atypical antipsychotics vs placebo

Psychosis ‐ presented in units of NPI‐NH P (higher is worse)d ‐ 3364 persons in 12 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Response for psychosis ‐ as defined by authors of RCTs ‐ 1958 persons in 7 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Atypical antipsychotics vs placebo

Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Somnolence

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
High

Atypical antipsychotics vs placebo

Death ‐ 5032 persons in 17 RCTs of 3 to 12 weeks ___________________________________________

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Specific behaviour ‐ agitation

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Response for agitation ‐ as defined by authors of RCTs ‐ 1303 persons in 4 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Typical vs atypical antipsychotics

All‐cause mortality · delirious patients

Typical showed no clear difference in mortality compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
RR 1.71 [0.82, 3.53]
4 studies · 342 participants
Moderate

Typical vs atypical antipsychotics

Length of hospital stay · delirious patients

The review found no eligible studies for this question.

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Typical vs atypical antipsychotics

Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · delirious patients

It is very uncertain whether typical changes adverse Effects ‐ EPS compared with atypical antipsychotics (very low certainty).

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
RR 12.16 [0.55, 269.52]
2 studies · 198 participants
Very low

Typical vs atypical antipsychotics

Duration of delirium Days · delirious patients

The review found no eligible studies for this question.

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Typical vs atypical antipsychotics

Delirium resolution DRS, DRS‐R981 · delirious patients

Typical showed no clear difference in delirium resolution DRS, DRS‐R981 compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
RR 1.1 [0.79, 1.52]
5 studies · 349 participants
Moderate

Typical vs atypical antipsychotics

Severity of delirium · delirious patients

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 542 participants
Moderate